Market Research Logo

Mantle Cell Lymphoma - Pipeline Review, H2 2015

Mantle Cell Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Mantle Cell Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Mantle Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Mantle Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mantle Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Mantle Cell Lymphoma Overview
Therapeutics Development
Pipeline Products for Mantle Cell Lymphoma - Overview
Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis
Mantle Cell Lymphoma - Therapeutics under Development by Companies
Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
Mantle Cell Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Mantle Cell Lymphoma - Products under Development by Companies
Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes
Mantle Cell Lymphoma - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Advancell
Affimed Therapeutics AG
Amgen Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Bayer AG
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EpiZyme, Inc.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Johnson & Johnson
Karyopharm Therapeutics, Inc.
LFB S.A.
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Nordic Nanovector ASA
Novartis AG
Onconova Therapeutics, Inc.
Onyx Pharmaceuticals, Inc.
Pfizer Inc.
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Selvita SA
Sorrento Therapeutics, Inc.
Stemline Therapeutics, Inc.
TG Therapeutics, Inc.
Mantle Cell Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
13197 - Drug Profile
AB-8779 - Drug Profile
abemaciclib - Drug Profile
abexinostat hydrochloride - Drug Profile
acadesine - Drug Profile
acalisib - Drug Profile
ACP-196 - Drug Profile
ACY-775 - Drug Profile
AFM-11 - Drug Profile
agatolimod sodium - Drug Profile
alisertib - Drug Profile
AMG-319 - Drug Profile
ASN-002 - Drug Profile
AT-7519 - Drug Profile
bendamustine hydrochloride - Drug Profile
Betalutin - Drug Profile
BLyS-gel - Drug Profile
BMS-986016 - Drug Profile
buparlisib hydrochloride - Drug Profile
carfilzomib - Drug Profile
CBM-C19.1 - Drug Profile
CBM-C20.1 - Drug Profile
CC-122 - Drug Profile
Cell Therapy for Oncology - Drug Profile
Cell Therapy to Target CD19 for Oncology - Drug Profile
Cell Therapy to Target ROR1 for Oncology - Drug Profile
cerdulatinib - Drug Profile
copanlisib hydrochloride - Drug Profile
daratumumab - Drug Profile
denintuzumab mafodotin - Drug Profile
duvelisib - Drug Profile
E-7449 - Drug Profile
entospletinib - Drug Profile
epratuzumab - Drug Profile
EPZ-015666 - Drug Profile
HMPL-523 - Drug Profile
ibrutinib - Drug Profile
ibrutinib + ublituximab + TGR-1202 - Drug Profile
idelalisib - Drug Profile
IGN-002 - Drug Profile
IMGN-529 - Drug Profile
IMMU-114 - Drug Profile
INA-01 - Drug Profile
INCB-39110 - Drug Profile
INCB-40093 - Drug Profile
inebilizumab - Drug Profile
ixazomib citrate - Drug Profile
JNJ-64052781 - Drug Profile
lenalidomide - Drug Profile
MEDI-0680 - Drug Profile
MEDI-551 + MEDI-0680 - Drug Profile
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile
Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile
MOR-208 - Drug Profile
ON-123300 - Drug Profile
ONC-201 - Drug Profile
pevonedistat hydrochloride - Drug Profile
polatuzumab vedotin - Drug Profile
ribociclib - Drug Profile
SEL-120 - Drug Profile
selinexor - Drug Profile
SGN-CD70A - Drug Profile
SL-101 - Drug Profile
Small Molecule for Mantle Cell Lymphoma - Drug Profile
temsirolimus - Drug Profile
TGR-1202 - Drug Profile
tisagenlecleucel-T - Drug Profile
tretinoin - Drug Profile
ublituximab - Drug Profile
venetoclax - Drug Profile
vorinostat - Drug Profile
Mantle Cell Lymphoma - Recent Pipeline Updates
Mantle Cell Lymphoma - Dormant Projects
Mantle Cell Lymphoma - Discontinued Products
Mantle Cell Lymphoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Mantle Cell Lymphoma, H2 2015
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Mantle Cell Lymphoma - Pipeline by AB Science SA, H2 2015
Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Advancell, H2 2015
Mantle Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015
Mantle Cell Lymphoma - Pipeline by Amgen Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Bayer AG, H2 2015
Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H2 2015
Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015
Mantle Cell Lymphoma - Pipeline by Eli Lilly and Company, H2 2015
Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Genentech, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015
Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015
Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H2 2015
Mantle Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2015
Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by LFB S.A., H2 2015
Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2015
Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H2 2015
Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015
Mantle Cell Lymphoma - Pipeline by Novartis AG, H2 2015
Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Selvita SA, H2 2015
Mantle Cell Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2015
Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015
Mantle Cell Lymphoma - Dormant Projects, H2 2015
Mantle Cell Lymphoma - Dormant Projects (Contd..1), H2 2015
Mantle Cell Lymphoma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Mantle Cell Lymphoma, H2 2015
Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report